A novel anti-CD3xCD28xSTEAP1 trispecific T-cell engager (HLX3902) with enhanced and durable antitumor responses in prostate cancer
科学论文
Serplulimab Combined with Chemotherapy in The Neoadjuvant Treatment of Resectable Oesophagexal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial
ESMO IO 2024
Serplulimab in combination with regorafenib and hepatic artery bicarbonate infusion on the third-line treatment in advanced colorectal cancer patients with liver metastasis: study protocol of a single-arm, single-center phase II study
CSCO 2024
First-Line Serplulimab for Advanced Squamous Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Real-World ASTRUM-004R Study
ESMO Aisa 2024
Is neoadjuvant chemoimmunotherapy better than chemotherapy in patients with limited-stage small cell lung cancer: a retrospective comparative study
WCLC 2024
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study
WCLC 2024
Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: an open-label, single-arm, phase 2 trial
